| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a6bf0817e1ee195a2e941715bbbb855c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_356403723155099905e07ba28c4834c9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0a910d33c239980f3a705e312c5bad6a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_21662ade8020c930267ca63e56b91297
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_945463db4bee5dddd01fd1edfc226f47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b6c0422ec65e063278fe98637622e245 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5042
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5026
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5084
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5386 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5386
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-22 |
| filingDate |
2009-02-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_19454ae0644418f272c019d8dc432e58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_05c0f709f195fe238b291bc4ecb79d81
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0608f0b693a2fc1f000baf86f38fb980
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_03b8006349f90b3b79fa2e76e6bda9b7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_49a4ed883e0e4529834e8dc3af84ee08 |
| publicationDate |
2009-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2009105023-A1 |
| titleOfInvention |
Pharmaceutical formulation comprising oxabispidines / 236 |
| abstract |
The present invention relates to modified release formulations comprising oxapispidines, such as the compound tert-butyl (2- {7- [2- (4-cyano-2-fluorophenoxy) ethyl] -9-oxa-3, 7-diazabicyclo- [3.3.1] non-3-yl} ethyl) carbamate. Said formulations are preferably in the form of multiple unit systems providing for an immediate release of drug in combination with an extended release of drug during a period of time of up to 24 hours. The compositions are useful in the treatment of cardiac arrhythmias and additionally providing the possibility for early detection of patients responding with an unfavourable QT prolongation. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104586809-A |
| priorityDate |
2008-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |